Ustekinumab is a monoclonal antibody that binds a protein subunit shared by two cytokines - interleukin-12 and interleukin-23 - blocking both pathways at once. Those pathways drive psoriasis, psoriatic arthritis and inflammatory bowel disease, so ustekinumab treats all three. That breadth matters because those conditions frequently occur together, and its dosing interval is unusually long.
Follow the plan your specialist gave you. This guide contains no doses.
It works in bowel disease
This is the practical distinction from IL-17 inhibitors. Secukinumab and its relatives clear psoriasis extremely well and can worsen Crohn's disease and ulcerative colitis - trials in Crohn's were stopped early because patients deteriorated.
Ustekinumab is licensed and effective in both Crohn's disease and ulcerative colitis.
So for someone with psoriasis or psoriatic arthritis and inflammatory bowel disease, ustekinumab treats both with one drug - as do the TNF inhibitors.
See secukinumab and adalimumab.
What it treats
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Crohn's disease and ulcerative colitis
NHS access is within defined criteria based on severity and previous treatments.
For skin, it works more slowly than IL-17 inhibitors - improvement builds over weeks to a few months rather than appearing quickly.
The dosing interval
For psoriasis, ustekinumab is given as an injection under the skin, with a second dose four weeks later, then every twelve weeks.
Four injections a year, after the first two, is a considerable practical advantage over weekly or fortnightly biologics.
For bowel disease, treatment starts with a single intravenous infusion in hospital, then subcutaneous injections every eight or twelve weeks.
The long interval means a missed dose matters more than with a frequently given drug - make sure you know your next date.
Screening before starting
Tuberculosis screening is required - history, chest X-ray and an interferon gamma release assay - along with hepatitis B and C serology.
Where latent TB is found, treatment for it is given before or alongside.
Report a persistent cough, fever, night sweats or unexplained weight loss at any point during treatment.
Infection
Serious infections are more common, though ustekinumab's overall infection rate is favourable compared with some other biologics.
Seek medical advice promptly for fever, persistent sore throat, a cough that will not settle, burning on passing urine, or a wound that is not healing.
Treatment is paused during a significant infection and restarted once it has resolved.
Carry your biologic alert card and show it to anyone treating you.
See infection risk on immune-suppressing medicines.
Vaccines
Live vaccines are avoided during treatment - yellow fever, MMR, live shingles vaccine and the live nasal flu vaccine for children.
Because of the long dosing interval, the gap needed before and after a live vaccine is longer than with other biologics - ask your team well in advance of travel.
Inactivated vaccines are recommended - annual influenza, pneumococcal, COVID and the non-live shingles vaccine.
See travel vaccines.
Injecting it
Subcutaneous injection into the thigh, abdomen or upper arm, rotating sites, using a pre-filled syringe.
Take it from the fridge and let it reach room temperature for around half an hour before injecting - cold solution stings considerably more.
Store in the fridge, never frozen, and use a cool bag for travel - see medicines that need the fridge.
Used devices go in a sharps bin - see needles and sharps disposal.
The needle cover of some presentations contains a latex derivative - tell your team if you have a latex allergy.
No routine blood monitoring
Unlike methotrexate and ciclosporin, ustekinumab does not require regular blood counts and liver tests.
See dupilumab, which shares that advantage.
Biosimilars
Biosimilar versions are now available and increasingly used. They are highly similar rather than identical, and approved on evidence of equivalent effect.
What usually changes is the device. If your product changes, ask to be shown it rather than assuming it works the same way.
See why some medicines are prescribed by brand.
If it stops working
Some people develop antibodies against ustekinumab over time, reducing its effect, though less often than with some other biologics.
Loss of effect after a period of good response is worth reporting rather than enduring. Options include shortening the interval between doses, or switching to a different biologic - risankizumab and guselkumab block IL-23 alone and are alternatives on the same pathway.
Other effects
Headache, fatigue, nasal symptoms, diarrhoea and injection site reactions are the common ones.
Report a new or worsening rash, and breathlessness with cough, since rare lung inflammation has been reported.
Non-melanoma skin cancer is somewhat more common with immune-modifying treatment, so sun protection matters and any new or changing skin lesion should be reported.
It has no significant drug interactions.
The Conditions section covers more on what medicines are prescribed for - Why Nerve Pain Needs Different Medicines is closely related to this one.